Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants

Luisa Galli; Andrea Novelli; Elena Chiappini; Paola Gervaso; Maria Iris Cassetta; Stefania Fallani; Maurizio de Martino

doi:10.1097/01.inf.0000261111.90075.4d

Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants

Pediatr Infect Dis J. 2007 May;26(5):451-3. doi: 10.1097/01.inf.0000261111.90075.4d.

Authors

Luisa Galli¹, Andrea Novelli, Elena Chiappini, Paola Gervaso, Maria Iris Cassetta, Stefania Fallani, Maurizio de Martino

Affiliation

¹ Departments of Pediatrics, University of Florence, Florence, Italy.

PMID: 17468661
DOI: 10.1097/01.inf.0000261111.90075.4d

Abstract

The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.

MeSH terms

Antiviral Agents / therapeutic use*
Cytomegalovirus Infections / congenital
Cytomegalovirus Infections / drug therapy*
Cytomegalovirus Infections / virology
DNA, Viral / analysis
Female
Ganciclovir / analogs & derivatives*
Ganciclovir / blood
Ganciclovir / therapeutic use
Humans
Infant
Infant, Newborn
Male
Pilot Projects
Valganciclovir
Viral Load

Substances

Antiviral Agents
DNA, Viral
Valganciclovir
Ganciclovir